Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned an average rating of “Buy” from the seventeen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $33.50.

A number of equities research analysts have commented on the stock. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Finally, Morgan Stanley dropped their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, August 18th.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $13.26 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -4.74 and a beta of 1.23. The stock’s 50-day moving average is $14.55 and its two-hundred day moving average is $14.35. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same period last year, the company earned ($0.59) EPS. Analysts forecast that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Activity

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 217,391 shares in the company, valued at $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 495,282 shares of the firm’s stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the sale, the chief executive officer directly owned 253,071 shares in the company, valued at approximately $3,796,065. The trade was a 66.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Denali Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Denali Therapeutics by 7.4% during the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock worth $189,000 after purchasing an additional 930 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Denali Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock valued at $548,000 after purchasing an additional 1,058 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 12.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock valued at $190,000 after purchasing an additional 1,543 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.